---
title: "Hengrui Pharma signed a licensing agreement for the Rykunkun Trastuzumab project with Glenmark Specialty"
description: "Hengrui Pharma signed a licensing agreement with Glenmark Specialty, granting a paid license for the SHR-A1811 project (RuiKang Trastuzumab) to Glenmark Specialty. Hengrui has granted Glenmark Special"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258669329.md"
published_at: "2025-09-24T09:49:03.000Z"
---

# Hengrui Pharma signed a licensing agreement for the Rykunkun Trastuzumab project with Glenmark Specialty

> Hengrui Pharma signed a licensing agreement with Glenmark Specialty, granting a paid license for the SHR-A1811 project (RuiKang Trastuzumab) to Glenmark Specialty. Hengrui has granted Glenmark Specialty exclusive rights to develop and commercialize the drug in multiple countries and regions, with an upfront payment of $18 million and potential milestone payments and sales royalties of up to $1.093 billion. This agreement will expand the overseas market for RuiKang Trastuzumab and enhance the company's innovative brand and performance

According to the news from Zhitong Finance APP, Hengrui Pharma (01276) announced that the company has reached an agreement with Glenmark Specialty S.A. (hereinafter referred to as "Glenmark Specialty") to grant a paid license for its independently developed Class 1 innovative drug SHR-A1811 (RuiKang Trastuzumab) project to Glenmark Specialty.

According to the agreement, Hengrui will grant Glenmark Specialty exclusive rights to develop and commercialize RuiKang Trastuzumab globally, except for mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan, the United States, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan. Glenmark Specialty will pay Hengrui an upfront payment of $18 million, and Hengrui will be eligible to receive milestone payments related to registration and sales, totaling up to $1.093 billion. Based on the sales performance of RuiKang Trastuzumab within the licensed scope, Glenmark Specialty will pay Hengrui corresponding sales commissions.

The signing of this agreement will help expand the overseas market for RuiKang Trastuzumab, providing high-quality treatment options for patients worldwide, and will further enhance the company's innovative brand and overseas performance. The company insists on balancing independent research and development with open cooperation, strengthening international collaboration based on endogenous development, achieving rapid transformation of research and development results, leveraging internationally leading partners to cover overseas markets, accelerating integration into the global drug innovation network, maximizing product value, and serving global patients with innovative products

### Related Stocks

- [01276.HK - HENGRUI PHARMA](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN - Hengrui Pharma](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug | Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug | [Link](https://longbridge.com/en/news/272359395.md) |
| Hengrui Pharma Gets Nod to Trial Six Drugs | Hengrui Pharma Gets Nod to Trial Six Drugs | [Link](https://longbridge.com/en/news/271064302.md) |
| CICC Reaffirms Their Buy Rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938) | In a report released yesterday, from CICC maintained a Buy rating on Suzhou Ribo Life Science Co., Ltd. Class H, with a  | [Link](https://longbridge.com/en/news/276199846.md) |
| Hengrui Pharma first three quarters revenue RMB23.20 billion | Hengrui Pharma first three quarters revenue RMB23.20 billion | [Link](https://longbridge.com/en/news/262893042.md) |
| Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials | Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials | [Link](https://longbridge.com/en/news/273791098.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
